After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Treasury yields are pushing higher amid another rally in energy prices; market mea sures of inflation expectations have reached their highest level since early-2023. Elsewhere, Magnificent Seven ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

A lidar scanner has a resolution so high it can image ridges and indentations of only 1 millimetre on objects hundreds of ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

courtesy Mariia Zelenina While floating underwater before cheerful children and other park guests, things quickly took a turn when one of the larger fish suddenly inhaled her head. Zelenina ...

Yellowhammer News reported on Jan. 29 that Green, 29, will join Red Level Strategies, which Yellowhammer described as president and CEO "Jeff Rabren’s quiet, yet viciously-effective firm." It said ...

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts ...

WASHINGTON — David Sundberg, the assistant director in charge of the FBI Washington Field Office, was notified Thursday that he was going to lose his job and is preparing to leave the bureau ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.